Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy

Neoadjuvant platin-based therapy is accepted as a standard therapy for advanced esophageal adenocarcinoma (EAC). Patients who respond have a better survival prognosis, but still a significant number of responder patients die from tumor recurrence. Molecular markers for prognosis in neoadjuvantly tre...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Aichler, Michaela, Motschmann, Martin, Jütting, Uta, Luber, Birgit, Becker, Karen, Ott, Katja, Lordick, Florian, Langer, Rupert, Feith, Marcus, Siewert, Jörg Rüdiger, Walch, Axel
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2014
Teme:
Clinical Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4196151/
https://ncbi.nlm.nih.gov/pubmed/25216514
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items